NASDAQ — Healthcare: Manufacturing, Biotechnology: Pharmaceutical Preparations
www.cyclacel.comCyclacel Pharmaceuticals, Inc. has until June 4, 2025, to regain compliance with Nasdaq's minimum bid price requirement of $1.00 per share following a notice of non-compliance received on December 6, 2024. The company's common stock was determined to have not met this requirement based on the closing bid price over the preceding 30 business days. Although the notice does not affect the current listing or trading of the common stock on Nasdaq, failure to comply within the grace period could result in delisting. Cyclacel is considering options including a potential reverse stock split to meet compliance standards, but it cannot guarantee success in this effort.
Compliance DeadlineDana-Farber Cancer Institute is set to complete a clinical trial (NCT03641755) on June 22, 2025, evaluating the safety and effectiveness of the combination of Olaparib and Sapacitabine in treating BRCA mutant breast cancer. Olaparib, an FDA-approved PARP inhibitor for metastatic HER2 negative breast cancer with a BRCA mutation, aims to impede cancer cell repair mechanisms. Conversely, while Sapacitabine has not received FDA approval for breast cancer, its antitumor properties have been noted against various cancers. The trial is currently active with an enrollment of 10 participants.
Clinical Trial CompletionCyclacel Pharmaceuticals, Inc. expects the completion of its clinical trial for Fadraciclib (CYC065) on June 30, 2025. This trial is examining the efficacy of Fadraciclib in patients with advanced solid tumors and lymphoma, specifically focusing on those who have failed all standard therapies or for whom no standard options exist. The study includes multiple groups targeting various cancer types, including endometrial, ovarian, biliary tract, breast, and types of lymphoma. Currently, the trial is in the recruiting phase with an enrollment count of 330 subjects.
clinical trial completionThe deadline for the share exchange transaction between Cyclacel Pharmaceuticals and FITTERS Diversified Berhad is set for August 31, 2025. This transaction, part of an agreement executed on May 6, 2025, involves Fitters Parent exchanging its ownership interest in Fitters for 19.99% of Cyclacel's common stock. If the transaction is not closed by the deadline, either party can terminate the agreement. Successful closure will result in Fitters becoming a wholly-owned subsidiary of Cyclacel, enhancing its strategic position in the market.
Corporate EventCyclacel Pharmaceuticals, Inc. is expected to complete its clinical trial investigating CYC140 in subjects with advanced solid tumors and lymphoma by November 1, 2025. The trial includes a Phase 1 dose-escalation and dose-finding component, followed by a Phase 2 segment enrolling around 330 patients with various advanced cancers, including bladder cancer, triple-negative breast cancer, and metastatic colorectal cancer. The study aims to provide treatment options for patients who have failed standard therapies or for whom no standard therapies are available, potentially advancing cancer treatment strategies.
Clinical Trial